HCC Clinical Trial
Official title:
A New Conception About Individualized Treatment Allocation for HCC-Using Machine Learning
The current guidelines on hepatocellular carcinoma (HCC) aimed to build effective prognostic stratification strategies to guide therapeutic allocation; however, the current guidelines did not consider the simultaneous comparison of distinct therapies in similar populations. Here, the investigators aimed to develop and validate a new, integrated prognostic scheme for HCC patients using artificial intelligence (AI) to simulate the survival outcomes of patients allocated to different treatments.
Given that liver resection (LR) and transarterial chemoembolization (TACE) are the mainstay curative and palliative therapies for HCC, respectively, patients who underwent LR or TACE were included in the study. Various prognostic AI algorithms were modeled using data from a large multi-institutional cohort, where LR and TACE were considered independent factors. The C-index, Brier score (BS), and area under the receiver operating characteristic curve (auROC) were calculated to estimate the AI models. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Not yet recruiting |
NCT05458115 -
Clinical Study of MRD Recurrence Monitoring After Surgical Resection of Hepatocellular Carcinoma
|
||
| Not yet recruiting |
NCT05022628 -
Clinical Study of Radiotherapy Combined With Donafenib for Neoadjuvant Treatment of Patients With HCC With Portal Vein Carcinoma Thrombosis
|
Phase 4 | |
| Enrolling by invitation |
NCT02256514 -
Open Label Trial of Immunotherapy for Advanced Liver Cancer
|
Phase 2 | |
| Not yet recruiting |
NCT06434480 -
SBRT in HCC With Oligoprogression on Atezo-Bev
|
N/A | |
| Completed |
NCT04542837 -
The Study of KN046 in Combination With Lenvatinib in Advanced Hepatocellular Carcinoma
|
Phase 2 | |
| Not yet recruiting |
NCT05025592 -
cTACE or DEB-TACE+HAIC Combined With Regorafenib ± Anti-PD1 Antibody for uHCC
|
||
| Completed |
NCT04172506 -
A Study to Evaluate the Efficacy and Safety of Anti-PD-1 Antibody AK105 in Patients With Selected Advanced Solid Tumors
|
Phase 1/Phase 2 | |
| Not yet recruiting |
NCT06024252 -
Efficacy, Safety, and Treatment Patterns of Transcatheter Arterial Chemoembolization (TACE) Combined With Atezolizumab and Bevacizumab in Unresectable Hepatocellular Carcinoma: a Multicenter, Retrospective, Observational Real-world Study
|
||
| Not yet recruiting |
NCT05840133 -
Study of Long Non-coding RNA SNHG15 as a Novel Biomarker in HBV Associated HCC
|
||
| Terminated |
NCT02785874 -
Statin With Palliative Therapy for HCC
|
N/A | |
| Not yet recruiting |
NCT02715492 -
Role of (LMWH) in Prevention of Thromboembolic Complication After (TACE) in Hepatocellular Carcinoma.
|
Phase 3 | |
| Completed |
NCT02985034 -
Safety Margin Assessment After RFA Using the Registration of Pre-ablation MRI and Post-ablation CT
|
N/A | |
| Not yet recruiting |
NCT06069947 -
SALT for Liver Cirrhosis With HCC
|
N/A | |
| Recruiting |
NCT05581004 -
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7502175 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors
|
Phase 1 | |
| Suspended |
NCT02935478 -
Bariatric Embolization of Arteries in Obese Patients With HCC to Allow Salvage Liver Transplantation
|
N/A | |
| Recruiting |
NCT05592171 -
Occlusafe® Assisted MW Alone or With DEB-TACE Compared to MW With DEB-TACE in the Treatment of HCC
|
N/A | |
| Completed |
NCT03176485 -
Evaluation of Pathway Modulation by Raf, MEK, & Kinase Inhibitors
|
N/A | |
| Recruiting |
NCT05544253 -
Safety and Efficacy of Mitomycin C-based HIPEC After srHCC and PM of HCC
|
Phase 2/Phase 3 | |
| Recruiting |
NCT06184152 -
CEUS vs. AMRI for HCC Detection in Patients With Indeterminate Liver Nodules
|
||
| Completed |
NCT02675920 -
A Study of HCC High Risk Group Using Two Surveillance Tools
|